A Coronavirus vaccine developed by the United States based biotechnology company Moderna in association with the National Institutes of Health is observed to induce immune responses in all the volunteers who received during a Phase 1 study.

These early results were published in the New England Journal of Medicine and displayed that the vaccine has yielded a good result as it triggered immune response with minimum side effects like fatigue, headache, muscle pain, and has become the first US vaccine candidate to publish results.

The vaccine will begin a Phase 3 trial later this month, and this trial is the final trial stage before regulators consider to make the vaccine available.The Phase 1 study involved 45 healthy adults, aged 18 to 55, who received two vaccinations of the vaccine candidate.